LeMaitre Vascular (LMAT) 10-Q 8 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	1-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'LMAT	'
Entity Registrant Name	'LEMAITRE VASCULAR INC	'
Entity Central Index Key	'0001158895	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	15,635,234

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$12,504	$14,711
Accounts receivable, net of allowances of $225 at March 31, 2014 and $263 at December 31, 2013	10,494	10,590
Inventory	14,186	13,255
Prepaid expenses and other current assets	3,151	3,169
Total current assets	40,335	41,725
Property and equipment, net	5,807	5,810
Goodwill	15,031	15,031
Other intangibles, net	5,758	6,144
Deferred tax assets	1,619	1,615
Other assets	168	167
Total assets	68,718	70,492
Current liabilities:	'	'
Accounts payable	1,040	1,235
Accrued expenses	6,868	7,993
Acquisition-related obligations	801	992
Total current liabilities	8,709	10,220
Deferred tax liabilities	3,475	3,461
Other long-term liabilities	298	249
Total liabilities	12,482	13,930
Stockholders' equity:	'	'
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding	'	'
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 16,982,730 shares at March 31, 2014, and 16,959,330 shares at December 31, 2013	170	170
Additional paid-in capital	65,209	65,354
Accumulated deficit	-874	-667
Accumulated other comprehensive loss	-226	-253
Treasury stock, at cost; 1,380,272 shares at March 31, 2014, and 1,380,119 shares at December 31, 2013	-8,043	-8,042
Total stockholders' equity	56,236	56,562
Total liabilities and stockholders' equity	$68,718	$70,492

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Accounts receivable, allowances	$225	$263
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	37,000,000	37,000,000
Common stock, shares issued	16,982,730	16,959,330
Treasury stock, at cost	1,380,272	1,380,119

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Net sales	$16,754	$15,382
Cost of sales	5,530	4,176
Gross profit	11,224	11,206
Sales and marketing	6,229	5,768
General and administrative	3,315	2,882
Research and development	1,344	1,273
Restructuring charges	403	'
Medical device excise tax	164	160
Total operating expenses	11,455	10,083
Income (loss) from operations	-231	1,123
Other income (expense):	'	'
Interest income	'	1
Interest expense	'	-4
Foreign currency loss	-42	-50
Income (loss) before income taxes	-273	1,070
Provision (benefit) for income taxes	-66	224
Net income (loss)	($207)	$846
Earnings per share of common stock:	'	'
Basic	($0.01)	$0.06
Diluted	($0.01)	$0.05
Weighted-average shares outstanding:	'	'
Basic	15,586	15,219
Diluted	15,586	15,648
Cash dividends declared per common share	$0.04	$0.03

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Comprehensive Income Net Of Tax [Abstract]	'	'
Net income (loss)	($207)	$846
Other comprehensive income:	'	'
Foreign currency translation adjustment, net	27	-295
Total other comprehensive income	27	-295
Comprehensive income (loss)	($180)	$551

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities	'	'
Net income (loss)	($207)	$846
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	831	610
Stock-based compensation	278	277
Provision for losses in accounts receivable	31	3
Provision for inventory write-downs	75	103
Excess tax benefits from stock-based compensation awards	-28	'
Loss on disposal of property and equipment	4	'
Foreign currency transaction loss	5	53
Changes in operating assets and liabilities:	'	'
Accounts receivable	68	-446
Inventory	-997	-619
Prepaid expenses and other assets	63	-48
Accounts payable and other liabilities	-1,812	-1,125
Net cash used in operating activities	-1,689	-346
Investing activities	'	'
Purchases of property and equipment	-433	-676
Payments related to acquisitions	-193	-111
Purchase of intellectual property	-13	-8
Net cash used in investing activities	-639	-795
Financing activities	'	'
Proceeds from issuance of common stock	96	170
Purchase of treasury stock	-1	-90
Excess tax benefits from stock-based compensation awards	28	'
Net cash provided in financing activities	123	80
Effect of exchange rate changes on cash and cash equivalents	-2	-85
Net decrease in cash and cash equivalents	-2,207	-1,146
Cash and cash equivalents at beginning of period	14,711	16,448
Cash and cash equivalents at end of period	$12,504	$15,302

Organization_and_Basis_for_Pre

Organization and Basis for Presentation	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Organization and Basis for Presentation	'
	1	Organization and Basis for Presentation
	Description of Business
	Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We operate in a single segment in which our principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. Our offices are located in Burlington, Massachusetts; Mississauga, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Tullamarine, Australia and Tokyo, Japan.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the three months ended March 31, 2014 are not necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2013, including the notes thereto, included in our Form 10-K filed with the Securities and Exchange Commission (SEC).
	Consolidation
	Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, and LeMaitre Vascular Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

Income_Tax_Expense

Income Tax Expense	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Expense	'
	2	Income Tax Expense
	As part of the process of preparing our consolidated financial statements we are required to determine our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent we believe that recovery is not likely, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must reflect this increase as an expense within the tax provision in the statement of operations. We do not provide for income taxes on undistributed earnings of foreign subsidiaries, as our current intention is to permanently reinvest these earnings.
	We recognize, measure, present and disclose in our financial statements uncertain tax positions that we have taken or expect to take on a tax return. We operate in multiple taxing jurisdictions, both within the United States and outside of the United States, and may be subject to audits from various tax authorities regarding transfer pricing, the deductibility of certain expenses, intercompany transactions, and other matters. Within specific countries, we may be subject to audit by various tax authorities operating within the country and may be subject to different statutes of limitation expiration dates. Management’s judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will continue to monitor the realizability of our deferred tax assets and adjust the valuation allowance accordingly.
	Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.
	Our 2014 income tax expense varies from the statutory rate mainly due to certain permanent items, a discrete item related to certain foreign branch losses previously not deductible and lower statutory rates from a mix of our foreign entities. Our 2013 income tax expense varies from the statutory rate mainly due to discrete items related to a research and development tax credit earned in 2012, but enacted into law in January 2013, lower statutory rates from our foreign entities and certain permanent items.
	We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2014 the gross amount of unrecognized tax benefits exclusive of interest and penalties was $162,000. We remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions until 2017. A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:
			2014
			(in thousands)
	Unrecognized tax benefits at the beginning of year		$	111
	Additions for tax positions of current year			51
	Additions for tax positions of prior years			—
	Reductions for tax positions of prior years			—
	Reductions for lapses of the applicable statutes of limitations			—
	Unrecognized tax benefits at the end of the period		$	162
	In March 2014, the German tax authority notified our German subsidiary that the tax years 2009 through 2012 would be audited. We expect the audit to commence during the third quarter of 2014. In May 2014, the French tax authority notified our French subsidiary that the tax years 2011 through 2013 would be audited. We expect the audit to commence during the second quarter of 2014. We believe there will be no material changes to our income tax liability as a result of these audits. We are not currently under audit in any other tax jurisdictions. As of March 31, 2014, a summary of the tax years that remain subject to examination in our taxing jurisdictions is as follows:
	United States			2010 and forward
	Foreign			2007 and forward

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	3	Inventories
	Inventories consist of the following:
			March 31, 2014		December 31, 2013
			(in thousands)
	Raw materials		$	3,730	$	3,647
	Work-in-process			2,492		2,949
	Finished products			7,964		6,659
	Total inventory		$	14,186	$	13,255
	We held inventory on consignment of $0.7 million as of March 31, 2014 and December 31, 2013, respectively.

Acquisition_and_Divestitures

Acquisition and Divestitures	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Acquisition and Divestitures	'
	4	Acquisition and Divestitures
	XenoSure Manufacturing and Distribution Rights
	In October 2012, we entered into an Asset Purchase Agreement (the Neovasc Agreement) with Neovasc, Inc. and its subsidiary, Neovasc Medical Inc. (collectively Neovasc) to acquire the manufacturing and distribution rights of the XenoSure biologic vascular patch. Previously, we were the exclusive distributor of the XenoSure biologic vascular patch through January 26, 2016 and held an option to purchase the manufacturing and distribution rights. Assets acquired in October 2012 include intellectual property, manufacturing know-how, and a five year non-compete agreement. Other provisions of the Neovasc Agreement include transitional assistance from Neovasc and mutual indemnification for losses arising out of or relating to certain breaches of, and misrepresentations under, the Neovasc Agreement. Additionally, we have entered into a supply agreement with Neovasc while we transition manufacturing to our Burlington facility.
	The purchase price for this acquisition was $4.6 million. We paid Neovasc $4.3 million at the closing of the acquisition. The remaining $0.3 million was paid in October 2013. We accounted for the acquisition as a business combination. We recorded $2.8 million of intangible assets and $1.8 million of goodwill. The weighted-average amortization period for the acquired intangible assets as of November 1, 2012 was 12.0 years. The goodwill will be deductible for tax purposes over 15 years.
	Clinical Instruments International, Inc.
	In July 2013, we entered into an Asset Purchase Agreement with Clinical Instruments International, Inc. (Clinical Instruments) to acquire substantially all the assets of Clinical Instruments for $1.1 million. We paid $0.9 million at the closing and the remaining $0.2 million is payable in October 2014. We accounted for the acquisition as a business combination. Assets acquired include inventory and intellectual property. We recorded $0.2 million of inventory, $0.3 million of intangible assets and $0.6 million of goodwill. The weighted-average amortization period for the acquired intangible assets as of July 31, 2013 was 5.7 years. The goodwill will be deductible for tax purposes over 15 years.
	InaVein LLC
	In August 2013, we entered into an Asset Purchase Agreement with InaVein LLC (InaVein) to acquire substantially all the assets of InaVein for $2.5 million and potential acquisition-related contingent consideration totaling $1.4 million in 2014 and 2015 dependent on the sales performance of the acquired business and the timing of regulatory approval in China. We paid $2.1 million at the closing and the remaining $0.4 million is payable in August 2014. We accounted for the acquisition as a business combination. Assets acquired include receivables, inventory, equipment, and intellectual property. Liabilities assumed include payables and service contracts. We recorded $0.8 million of tangible assets, $1.1 million of intangible assets, $0.7 million of goodwill, and $0.1 million of assumed liabilities. The weighted-average amortization period for the acquired intangible assets as of August 31, 2013 was 6.7 years. The goodwill will be deductible for tax purposes over 15 years. We recorded $0.1 million as the fair value of contingent consideration as of March 31, 2014.
	Medistim Norge AS Distribution Agreement
	In October 2013, we entered into a definitive agreement with Medistim Norge AS (Medistim) to terminate its distribution of our products in Norway and to acquire certain assets and rights from Medistim effective as of January 1, 2014 for $0.2 million. The purchase price is due in three installments with payments made in October 2013 and January 2014 with the final payment due in December 2014. We allocated the payment to the tangible and intangible assets acquired based on the estimated fair value of each of these elements to the transaction. The weighted-average amortization period for these intangibles as of December 31, 2013 was 3.5 years.
	Tag Medical Pty Ltd Distribution Agreement
	In October 2013, we entered into a definitive agreement with Tag Medical Pty Ltd (Tag) to terminate its distribution of our products in Australia and to acquire certain assets and rights from Tag effective as of January 1, 2014 for $0.2 million. The purchase price is due in three installments with payments made in November 2013 and January 2014 and the final payment due in December 2014. We allocated the payment to the tangible and intangible assets acquired based on the estimated fair value of each of these elements to the transaction. The weighted-average amortization period for these intangibles as of December 31, 2013 was 4.8 years.
	Our acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses’ products, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure. The net assets acquired have been recorded based on estimates of fair value and, for acquisitions completed within the past year, are subject to adjustment upon finalization of the valuation process.
	The fair market valuations associated with these transactions fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long range strategic plans and other estimates.

Goodwill_and_Other_Intangibles

Goodwill and Other Intangibles	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangibles	'
	5	Goodwill and Other Intangibles
	There were no changes in the goodwill carrying amount of $15.0 million during the three months ended March 31, 2014.
	The components of our identifiable intangible assets were as follows:
			March 31, 2014						December 31, 2013
			Gross				Net		Gross				Net
			Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
			Value		Amortization		Value		Value		Amortization		Value
			(in thousands)
	Patents		$	5,691	$	2,094	$	3,597	$	5,679	$	1,932	$	3,747
	Trademarks and technology licenses			1,416		970		446		1,414		935		479
	Customer relationships			2,837		1,581		1,256		2,835		1,441		1,394
	Other intangible assets			971		512		459		971		447		524
	Total identifiable intangible assets		$	10,915	$	5,157	$	5,758	$	10,899	$	4,755	$	6,144
	These intangible assets are being amortized over their useful lives ranging from 1 to 13 years. The weighted-average amortization period for these intangibles as of March 31, 2014 is 6.9 years. Amortization expense is included in general and administrative expense and is as follows:
			Three months ended March 31,
			2014		2013
			(in thousands)
	Amortization expense		$	399	$	262
	Estimated amortization expense for the remainder of 2014 and each of the five succeeding fiscal years is as follows:
			2014		2015		2016		2017		2018		2019
			(in thousands)
	Amortization expense		$	1,011	$	1,009	$	866	$	608	$	493	$	383

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Accrued Expenses	'
	6	Accrued Expenses
	Accrued expenses consist of the following:
			March 31, 2014		December 31, 2013
			(in thousands)
	Compensation and related taxes		$	3,251	$	4,710
	Income and other taxes			756		885
	Dividend payable			546		—
	Professional fees			425		428
	Restructuring charges			353		—
	Other			1,537		1,970
	Total		$	6,868	$	7,993

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2014
Restructuring And Related Activities [Abstract]	'
Restructuring	'
	7	Restructuring
	In February 2014, we committed to a plan intended to improve operational efficiencies, which included a reduction in force of approximately 10% of our workforce and other cost-cutting measures, including the transfer of our recently acquired Clinical Instruments manufacturing to our Burlington headquarters and corresponding closure of our Southbridge manufacturing facility. As a result, we recorded approximately $0.4 million of severance related restructuring expense for the three months ended March 31, 2014.
	Activity related to accrued restructuring costs is as follows:
			Three months
			ended
			March 31, 2014
			(in thousands)
	Balance at beginning of year		$	—
	Plus:
	Current year restructuring costs			403
	Less:
	Payment of employee severance costs			50
	Balance at end of period		$	353
	We committed to an additional reduction in force of approximately 7 employees in April 2014. We estimate that termination costs will be $0.1 million to $0.2 million, and we expect to record the majority of these charges in the second quarter of 2014.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	8	Commitments and Contingencies
	Purchase Commitments
	As of March 31, 2014, as part of our normal course of business, we have purchase commitments to purchase $3.9 million of inventory through 2015.

Segment_and_EnterpriseWide_Dis

Segment and Enterprise-Wide Disclosures	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment and Enterprise-Wide Disclosures	'
	9	Segment and Enterprise-Wide Disclosures
	The FASB establishes standards for reporting information regarding operating segments in financial statements. Operating segments are identified as components of an enterprise about which separate, discrete financial information is evaluated by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as one operating segment. No discrete operating information is prepared by us except for product sales by product line and by legal entity for local reporting purposes.
	Most of our revenues were generated in the United States, Germany, Japan, Canada, and other European countries, and substantially all of our assets are located in the United States. Net sales to unaffiliated customers by country were as follows:
			Three months ended
			March 31,
			2014		2013
			(in thousands)
	United States		$	10,001	$	9,735
	Germany			1,880		1,559
	Japan			556		559
	Other countries			4,317		3,529
	Net Sales		$	16,754	$	15,382

Sharebased_Compensation

Share-based Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-based Compensation	'
	10	Share-based Compensation
	Our 2006 Stock Option and Incentive Plan allows for granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, unrestricted stock awards, and deferred stock awards to our officers, employees, directors, and consultants.
	The components of share-based compensation expense were as follows:
			Three months ended
			March 31,
			2014		2013
			(in thousands)
	Stock option awards		$	198	$	168
	Restricted stock units			80		109
	Total share-based compensation		$	278	$	277
	We did not issue option grants in the three months ended March 31, 2014 and 2013. We did not issue restricted stock unit grants in the three months ended March 31, 2014 and 2013.
	We issued approximately 23,000 and 46,000 shares of common stock following the exercise or vesting of underlying stock options or restricted stock units in the three months ended March 31, 2014 and 2013, respectively.

Net_Income_per_Share

Net Income per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Income per Share	'
	11	Net Income per Share
	The computation of basic and diluted net income per share was as follows:
			Three months ended
			March 31,
			2014			2013
			(in thousands, except per share data)
	Basic:
	Net income (loss) available for common stockholders		$	(207	)	$	846
	Weighted average shares outstanding			15,586			15,219
	Basic earnings per share		$	(0.01	)	$	0.06
	Diluted:
	Net income (loss) available for common stockholders		$	(207	)	$	846
	Weighted-average shares outstanding			15,586			15,219
	Common stock equivalents, if diluted			—			429
	Shares used in computing diluted earnings per common share			15,586			15,648
	Diluted earnings per share		$	(0.01	)	$	0.05
	Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive			616			505

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	12	Stockholders’ Equity
	Authorized Shares
	On June 14, 2012, our stockholders approved an amendment (Charter Amendment) to our Second Amended and Restated Certificate of Incorporation to reduce the number of authorized shares of common stock from 100,000,000 to 37,000,000 shares and of undesignated preferred stock from 5,000,000 to 3,000,000 shares. The Charter Amendment was previously approved by our Board of Directors on April 12, 2012, subject to approval by our stockholders. The Charter Amendment was filed with the Secretary of State of the State of Delaware on June 14, 2012.
	Stock Repurchase Plan
	In July 2009, our Board of Directors authorized a repurchase of our common stock from time to time on the open market or in privately negotiated transactions. In November 2011, our Board of Directors increased this authorization to $10.0 million and extended the program through December 31, 2013. The timing and number of any shares repurchased were determined based on our evaluation of market conditions and other factors. Repurchases were also made under a Rule 10b5-1 plan, which would permit shares to be repurchased when we might otherwise be precluded from doing so under insider trading laws. Our last repurchases occurred during the three months ended March 31, 2013 in which we purchased approximately 15,000 shares for approximately $0.1 million. The repurchase program concluded as of December 31, 2013.
	Dividends
	In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:
	Record Date		Payment Date		Per Share Amount		Dividend Payment
							(in thousands)
	Fiscal Year 2014
	March 20, 2014			April 3, 2014	$	0.035	$	546
	Fiscal Year 2013
	March 20, 2013			3-Apr-13	$	0.03	$	457
	May 22, 2013			5-Jun-13	$	0.03	$	457
	August 21, 2013			September 4, 2013	$	0.03	$	460
	November 20, 2013			4-Dec-13	$	0.03	$	464
	On April 24, 2014, our Board of Directors approved a quarterly cash dividend on our common stock of $0.035 per share payable on June 5, 2014 to stockholders of record at the close of business on May 22, 2014, which will total approximately $0.5 million.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2014
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Cash Flow Information	'
	13	Supplemental Cash Flow Information
			Three months ended
			March 31,
			2014		2013
			(in thousands)
	Cash paid (refunded) for income taxes, net		$	124	$	97

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	14	Fair Value Measurements
	The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
		•	Level 1 — Quoted prices in active markets for identical assets or liabilities.
		•	Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
		•	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
	As of March 31, 2014, we had cash equivalents in a money market fund that was valued using Level 1 inputs (quoted market prices for identical assets) at a fair value of $8.3 million.
	We had no Level 2 assets being measured at fair value on a recurring basis as of March 31, 2014.
	As discussed in Note 4, we have certain acquisition-related contingent liabilities that were measured using Level 3 techniques based on an assessment of the probability that we would be required to make such future payment. There were no changes to the acquisition-related contingent liabilities during the three months ended March 31, 2014 and the balance was $0.1 million as of March 31, 2014 and December 31, 2013.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Loss	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Accumulated Other Comprehensive Loss	'
	15	Accumulated Other Comprehensive Loss
	Our accumulated other comprehensive loss consisted of foreign currency translation for the three months ended March 31, 2014 and 2013, respectively.
			Three months ended
			March 31,
			2014			2013
	Beginning balance		$	(253	)	$	(433	)
	Other comprehensive income (loss) before reclassifications			27			(295	)
	Amounts reclassified from accumulated other comprehensive loss			—			—
	Net current period other comprehensive income (loss)			27			(295	)
	Ending Balance		$	(226	)	$	(728	)

Organization_and_Basis_for_Pre1

Organization and Basis for Presentation (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Description of Business	'
	Description of Business
	Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We operate in a single segment in which our principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. Our offices are located in Burlington, Massachusetts; Mississauga, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Tullamarine, Australia and Tokyo, Japan.
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the three months ended March 31, 2014 are not necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2013, including the notes thereto, included in our Form 10-K filed with the Securities and Exchange Commission (SEC).
Consolidation	'
	Consolidation
	Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, and LeMaitre Vascular Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

Income_Tax_Expense_Tables

Income Tax Expense (Tables)	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	'
	A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:
		2014
		(in thousands)
	Unrecognized tax benefits at the beginning of year	$	111
	Additions for tax positions of current year		51
	Additions for tax positions of prior years		—
	Reductions for tax positions of prior years		—
	Reductions for lapses of the applicable statutes of limitations		—
	Unrecognized tax benefits at the end of the period	$	162
Summary of Tax Years Subject to Examination in Most Significant Tax Jurisdictions	'
	As of March 31, 2014, a summary of the tax years that remain subject to examination in our taxing jurisdictions is as follows:
	United States		2010 and forward
	Foreign		2007 and forward

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Summary of Inventories	'
	Inventories consist of the following:
		March 31, 2014		December 31, 2013
		(in thousands)
	Raw materials	$	3,730	$	3,647
	Work-in-process		2,492		2,949
	Finished products		7,964		6,659
	Total inventory	$	14,186	$	13,255

Goodwill_and_Other_Intangibles1

Goodwill and Other Intangibles (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Components of Identifiable Intangible Assets	'
	The components of our identifiable intangible assets were as follows:
		March 31, 2014						December 31, 2013
		Gross				Net		Gross				Net
		Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
		Value		Amortization		Value		Value		Amortization		Value
		(in thousands)
	Patents	$	5,691	$	2,094	$	3,597	$	5,679	$	1,932	$	3,747
	Trademarks and technology licenses		1,416		970		446		1,414		935		479
	Customer relationships		2,837		1,581		1,256		2,835		1,441		1,394
	Other intangible assets		971		512		459		971		447		524
	Total identifiable intangible assets	$	10,915	$	5,157	$	5,758	$	10,899	$	4,755	$	6,144
Amortization Expense Included in General and Administrative Expense	'
	Amortization expense is included in general and administrative expense and is as follows:
		Three months ended March 31,
		2014		2013
		(in thousands)
	Amortization expense	$	399	$	262
Estimated Amortization Expense for Remainder of 2014 and Each of Five Succeeding Fiscal Years	'
	Estimated amortization expense for the remainder of 2014 and each of the five succeeding fiscal years is as follows:
		2014		2015		2016		2017		2018		2019
		(in thousands)
	Amortization expense	$	1,011	$	1,009	$	866	$	608	$	493	$	383

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Accrued Expenses	'
	Accrued expenses consist of the following:
		March 31, 2014		December 31, 2013
		(in thousands)
	Compensation and related taxes	$	3,251	$	4,710
	Income and other taxes		756		885
	Dividend payable		546		—
	Professional fees		425		428
	Restructuring charges		353		—
	Other		1,537		1,970
	Total	$	6,868	$	7,993

Restructuring_Tables

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2014
Restructuring And Related Activities [Abstract]	'
Activity Related to Accrued Restructuring Costs	'
	Activity related to accrued restructuring costs is as follows:
		Three months
		ended
		March 31, 2014
		(in thousands)
	Balance at beginning of year	$	—
	Plus:
	Current year restructuring costs		403
	Less:
	Payment of employee severance costs		50
	Balance at end of period	$	353

Segment_and_EnterpriseWide_Dis1

Segment and Enterprise-Wide Disclosures (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Net Sales to Unaffiliated Customers by Geography	'
	Net sales to unaffiliated customers by country were as follows:
		Three months ended
		March 31,
		2014		2013
		(in thousands)
	United States	$	10,001	$	9,735
	Germany		1,880		1,559
	Japan		556		559
	Other countries		4,317		3,529
	Net Sales	$	16,754	$	15,382

Sharebased_Compensation_Tables

Share-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-based Compensation Expense	'
	The components of share-based compensation expense were as follows:
		Three months ended
		March 31,
		2014		2013
		(in thousands)
	Stock option awards	$	198	$	168
	Restricted stock units		80		109
	Total share-based compensation	$	278	$	277

Net_Income_per_Share_Tables

Net Income per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Net Income per Share	'
	The computation of basic and diluted net income per share was as follows:
		Three months ended
		March 31,
		2014			2013
		(in thousands, except per share data)
	Basic:
	Net income (loss) available for common stockholders	$	(207	)	$	846
	Weighted average shares outstanding		15,586			15,219
	Basic earnings per share	$	(0.01	)	$	0.06
	Diluted:
	Net income (loss) available for common stockholders	$	(207	)	$	846
	Weighted-average shares outstanding		15,586			15,219
	Common stock equivalents, if diluted		—			429
	Shares used in computing diluted earnings per common share		15,586			15,648
	Diluted earnings per share	$	(0.01	)	$	0.05
	Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		616			505

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Dividend Activity	'
	The dividend activity for the periods presented is as follows:
	Record Date	Payment Date		Per Share Amount		Dividend Payment
						(in thousands)
	Fiscal Year 2014
	March 20, 2014		April 3, 2014	$	0.035	$	546
	Fiscal Year 2013
	March 20, 2013		3-Apr-13	$	0.03	$	457
	May 22, 2013		5-Jun-13	$	0.03	$	457
	August 21, 2013		September 4, 2013	$	0.03	$	460
	November 20, 2013		4-Dec-13	$	0.03	$	464

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2014
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Cash Flow Information	'
		Three months ended
		March 31,
		2014		2013
		(in thousands)
	Cash paid (refunded) for income taxes, net	$	124	$	97

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Summary of Accumulated Other Comprehensive Loss	'
	Our accumulated other comprehensive loss consisted of foreign currency translation for the three months ended March 31, 2014 and 2013, respectively.
		Three months ended
		March 31,
		2014			2013
	Beginning balance	$	(253	)	$	(433	)
	Other comprehensive income (loss) before reclassifications		27			(295	)
	Amounts reclassified from accumulated other comprehensive loss		—			—
	Net current period other comprehensive income (loss)		27			(295	)
	Ending Balance	$	(226	)	$	(728	)

Income_Tax_Expense_Additional_

Income Tax Expense - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Unrecognized tax benefits exclusive of interest and penalties, gross	$162	$111
Statute of limitations expiration period	'Until 2017	'
Income tax examination period	'the German tax authority notified our German subsidiary that the tax years 2009 through 2012 would be audited.	'

Income_Tax_Expense_Reconciliat

Income Tax Expense - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Unrecognized tax benefits at the beginning of year	$111
Additions for tax positions of current year	51
Additions for tax positions of prior years	'
Reductions for tax positions of prior years	'
Reductions for lapses of the applicable statutes of limitations	'
Unrecognized tax benefits at the end of the period	$162

Income_Tax_Expense_Summary_of_

Income Tax Expense - Summary of Tax Years Subject to Examination in Most Significant Tax Jurisdictions (Detail)	3 Months Ended
	Mar. 31, 2014
United States [Member]	'
Income Tax Examination [Line Items]	'
Income tax year under examination	'2010 and forward
Foreign [Member]	'
Income Tax Examination [Line Items]	'
Income tax year under examination	'2007 and forward

Inventories_Summary_of_Invento

Inventories - Summary of Inventories (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$3,730	$3,647
Work-in-process	2,492	2,949
Finished products	7,964	6,659
Total inventory	$14,186	$13,255

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Inventory on consignment	$0.70	$0.70

Acquisitions_and_Divestitures_

Acquisitions and Divestitures - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Oct. 31, 2013

Mar. 31, 2014

Nov. 01, 2012

Oct. 31, 2012

Oct. 31, 2013

Oct. 31, 2012

Mar. 31, 2014

Jul. 31, 2013

Mar. 31, 2014

Aug. 31, 2013

Mar. 31, 2014

Medistim [Member]

Medistim [Member]

Medistim [Member]

Tag Medical Pty Ltd [Member]

Tag Medical Pty Ltd [Member]

Tag Medical Pty Ltd [Member]

XenoSure [Member]

XenoSure [Member]

XenoSure [Member]

XenoSure [Member]

XenoSure [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

InaVein LLC [Member]

InaVein LLC [Member]

Non-compete Agreement [Member]

Non-compete Agreement [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price for acquisition of assets and rights

'

'

'

'

$200,000

'

'

$200,000

'

'

$4,600,000

'

'

'

'

$1,100,000

$2,500,000

'

Acquisition date of assets and rights

'

'

'

'

'

1-Jan-14

'

'

1-Jan-14

'

'

'

'

31-Oct-12

'

30-Jul-13

30-Aug-13

'

Cash paid for assets purchased

193,000

111,000

'

'

'

'

'

'

'

'

4,300,000

'

'

'

'

900,000

2,100,000

'

Cash paid for manufacturing and distribution rights

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

Intangible assets

'

'

'

'

'

'

'

'

'

'

2,800,000

'

'

'

300,000

'

1,100,000

'

Goodwill

'

'

'

'

'

'

'

'

'

'

1,800,000

'

'

'

600,000

'

700,000

'

Maximum goodwill deductible for tax purposes

'

'

'

'

'

'

'

'

'

'

'15 years

'

'

'

'15 years

'

'15 years

'

Weighted-average amortization period for acquired intangible assets

'6 years 10 months 24 days

'

'

'3 years 6 months

'

'

'4 years 9 months 18 days

'

'

'12 years

'

'

'5 years

'

'

'5 years 8 months 12 days

'6 years 8 months 12 days

'

Balance payable to Clinical Instruments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

400,000

'

Inventory

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

Acquisition-related contingent consideration

100,000

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

'

Tangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

Assumed liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

Fair value of contingent consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

Purchase price installments description

'

'

'

'

'The purchase price is due in three installments with payments made in October 2013 and January 2014 with the final payment due in December 2014.

'

'

'The purchase price is due in three installments with payments made in November 2013 and January 2014 and the final payment due in December 2014

'

'

'

'

'

'

'

'

'

'

Goodwill_and_Other_Intangibles2

Goodwill and Other Intangibles - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Goodwill carrying amount	$15,031	$15,031
Weighted-average amortization period for intangibles	'6 years 10 months 24 days	'
Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets useful lives	'13 years	'
Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets useful lives	'1 year	'

Goodwill_and_Other_Intangibles3

Goodwill and Other Intangibles - Components of Identifiable Intangible Assets (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	$10,915	$10,899
Accumulated Amortization	5,157	4,755
Net Carrying Value of Intangible Assets	5,758	6,144
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	5,691	5,679
Accumulated Amortization	2,094	1,932
Net Carrying Value of Intangible Assets	3,597	3,747
Trademarks and Technology Licenses [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	1,416	1,414
Accumulated Amortization	970	935
Net Carrying Value of Intangible Assets	446	479
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	2,837	2,835
Accumulated Amortization	1,581	1,441
Net Carrying Value of Intangible Assets	1,256	1,394
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	971	971
Accumulated Amortization	512	447
Net Carrying Value of Intangible Assets	$459	$524

Goodwill_and_Other_Intangibles4

Goodwill and Other Intangibles - Amortization Expense Included in General and Administrative Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
Amortization expense	$399	$262

Goodwill_and_Other_Intangibles5

Goodwill and Other Intangibles - Estimated Amortization Expense for Remainder of 2014 and Each of Five Succeeding Fiscal Years (Detail) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
Amortization expense, Remainder of Fiscal Year 2014	$1,011
Amortization expense, Fiscal Year 2015	1,009
Amortization expense, Fiscal Year 2016	866
Amortization expense, Fiscal Year 2017	608
Amortization expense, Fiscal Year 2018	493
Amortization expense, Fiscal Year 2019	$383

Accrued_Expenses_Accrued_Expen

Accrued Expenses - Accrued Expenses (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Compensation and related taxes	$3,251	$4,710
Income and other taxes	756	885
Dividend payable	546	'
Professional fees	425	428
Restructuring charges	353	'
Other	1,537	1,970
Total	$6,868	$7,993

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	1 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2014	Mar. 31, 2014	Apr. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
			Subsequent Event [Member]	Minimum [Member]	Maximum [Member]
			Employees	Scenario, Forecast [Member]	Scenario, Forecast [Member]
Loss Contingencies [Line Items]	'	'	'	'	'
Percentage of reduction in work force	10.00%	'	'	'	'
Severance costs	'	$0.40	'	$0.10	$0.20
Employees terminated	'	'	7	'	'

Restructuring_Activity_Related

Restructuring - Activity Related to Accrued Restructuring Costs (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Reorganizations [Abstract]	'
Balance at beginning of year	'
Plus: Current year restructuring costs	403
Less: Payment of employee severance costs	50
Balance at end of period	$353

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	Mar. 31, 2014
In Millions, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
Commitments to purchase inventory	$3.90
Purchase commitments inventory expire year	'2015

Segment_and_EnterpriseWide_Dis2

Segment and Enterprise-Wide Disclosures - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
	Segment
Segment Reporting [Abstract]	'
Number of operating segments	1

Segment_and_EnterpriseWide_Dis3

Segment and Enterprise-Wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Net sales	$16,754	$15,382
United States [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Net sales	10,001	9,735
Germany [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Net sales	1,880	1,559
Japan [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Net sales	556	559
Other Countries [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Net sales	$4,317	$3,529

Sharebased_Compensation_Shareb

Share-based Compensation - Share-based Compensation Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'
Total share-based compensation	$278	$277
Stock Option Awards [Member]	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'
Total share-based compensation	198	168
Restricted Stock Units [Member]	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'
Total share-based compensation	$80	$109

Sharebased_Compensation_Additi

Share-based Compensation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Option grants issued	0	0
Restricted stock issued	0	0
Issue of common stock	23,000	46,000

Net_Income_per_Share_Computati

Net Income per Share - Computation of Basic and Diluted Net Income per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Basic:	'	'
Net income (loss) available for common stockholders	($207)	$846
Weighted average shares outstanding	15,586	15,219
Basic earnings per share	($0.01)	$0.06
Diluted:	'	'
Net income (loss) available for common stockholders	($207)	$846
Weighted-average shares outstanding	15,586	15,219
Common stock equivalents, if diluted	'	429
Shares used in computing diluted earnings per common share	15,586	15,648
Diluted earnings per share	($0.01)	$0.05
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive	616	505

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Apr. 24, 2014	Jun. 14, 2012	Jun. 14, 2012
In Millions, except Share data, unless otherwise specified			Common Stock [Member]	Subsequent Event [Member]	Maximum [Member]	Minimum [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Common stock, shares authorized	37,000,000	37,000,000	'	'	100,000,000	37,000,000
Preferred stock, shares authorized	3,000,000	3,000,000	'	'	5,000,000	3,000,000
Repurchase of common stock	'	'	$10	'	'	'
Repurchase of common stock, number of shares	'	'	15,000	'	'	'
Repurchase of common stock, value	'	'	0.1	'	'	'
Cash dividend on common stock per share	'	'	'	$0.04	'	'
Dividend payment date	'	'	'	5-Jun-14	'	'
Dividends payment amount	'	'	'	$0.50	'	'
Dividend record date	'	'	'	22-May-14	'	'

Stockholders_Equity_Dividend_A

Stockholders' Equity - Dividend Activity (Detail) (USD $)

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Apr. 24, 2014

Feb. 28, 2011

Mar. 31, 2014

Apr. 03, 2014

Feb. 28, 2011

Mar. 31, 2013

Apr. 03, 2013

Feb. 28, 2011

Mar. 31, 2013

Jun. 05, 2013

Feb. 28, 2011

Mar. 31, 2013

Sep. 04, 2013

Feb. 28, 2011

Mar. 31, 2013

Dec. 04, 2013

Subsequent Event [Member]

Installment 1 FY 2014 [Member]

Installment 1 FY 2014 [Member]

Installment 1 FY 2014 [Member]

Installment 1 FY 2013 [Member]

Installment 1 FY 2013 [Member]

Installment 1 FY 2013 [Member]

Installment 2 FY 2013 [Member]

Installment 2 FY 2013 [Member]

Installment 2 FY 2013 [Member]

Installment 3 FY 2013 [Member]

Installment 3 FY 2013 [Member]

Installment 3 FY 2013 [Member]

Installment 4 FY 2013 [Member]

Installment 4 FY 2013 [Member]

Installment 4 FY 2013 [Member]

Subsequent Event [Member]

Dividends Payable [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Record Date

'

'

22-May-14

'

20-Mar-14

'

'

20-Mar-13

'

'

22-May-13

'

'

21-Aug-13

'

'

20-Nov-13

'

Payment Date

'

'

5-Jun-14

'

3-Apr-14

'

'

3-Apr-13

'

'

5-Jun-13

'

'

4-Sep-13

'

'

4-Dec-13

'

Per Share Amount

$0.04

$0.03

'

$0.04

'

'

$0.03

'

'

$0.03

'

'

$0.03

'

'

$0.03

'

'

Dividend Payment

$546

'

'

'

'

$546

'

'

$457

'

'

$457

'

'

$460

'

'

$464

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information - Supplemental Cash Flow Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Supplemental Cash Flow Elements [Abstract]	'	'
Cash paid (refunded) for income taxes, net	$124	$97

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Acquisition-related contingent liabilities	$100,000	$100,000
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents in money market fund	8,300,000	'
Recurring [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets measured at fair value	$0	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Loss - Summary of Accumulated Other Comprehensive Loss (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Equity [Abstract]	'	'
Beginning balance	($253)	($433)
Other comprehensive income (loss) before reclassifications	27	-295
Amounts reclassified from accumulated other comprehensive loss	'	'
Net current period other comprehensive income (loss)	27	-295
Ending Balance	($226)	($728)